نتایج جستجو برای: cyp2d6

تعداد نتایج: 2395  

2017
Hitoshi Zembutsu Seigo Nakamura Sadako Akashi-Tanaka Takashi Kuwayama Chie Watanabe Tomoko Takamaru Hiroyuki Takei Takashi Ishikawa Kana Miyahara Hiroshi Matsumoto Yoshie Hasegawa Goro Kutomi Hiroaki Shima Fukino Satomi Minoru Okazaki Hisamitsu Zaha Mai Onomura Ayami Matsukata Yasuaki Sagara Shinichi Baba Akimitsu Yamada Kazuhiro Shimada Daisuke Shimizu Koichiro Tsugawa Arata Shimo Ern Yu Tan Mikael Hartman Ching-Wan Chan Soo Chin Yusuke Nakamura

Purpose: CYP2D6 is the key enzyme responsible for the generation of the potent active metabolite of tamoxifen, "endoxifen." There are still controversial reports questioning the association between CYP2D6 genotype and tamoxifen efficacy. Hence, we performed a prospective multicenter study to evaluate the clinical effect of CYP2D6 genotype on tamoxifen therapy. Experimental Design:We enrolled 27...

Journal: :Journal of neurology, neurosurgery, and psychiatry 1994
V Planté-Bordeneuve M B Davis D M Maraganore C D Marsden A E Harding

Recent molecular genetic studies of the cytochrome P-450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant alleles in patients with Parkinson's disease compared with controls. This indicates that the CYP2D6 locus confers genetic susceptibility to Parkinson's disease. CYP2D6 polymorphism has been investigated in 48 patients with familial Parkinson's diseas...

2013
Danny W. K. Lum Pablo Perel Aroon D. Hingorani Michael V. Holmes

OBJECTIVE To evaluate evidence on the association between CYP2D6 genotype and tamoxifen response through. DESIGN Systematic review and meta-analysis of prospective, cross-sectional and case-control studies published to 2012. For each study, relative risks and 95% confidence intervals were extracted and pooled with a fixed and random effects model. Heterogeneity, publication bias, subgroup, an...

2017
Werner Schroth Stefan Winter Thomas Mürdter Elke Schaeffeler Diana Eccles Bryony Eccles Balram Chowbay Chiea C. Khor Arafat Tfayli Nathalie K. Zgheib Michel Eichelbaum Matthias Schwab Hiltrud Brauch

Purpose: Prediction of impaired tamoxifen (TAM) to endoxifen metabolism may be relevant to improve breast cancer treatment, e.g., via TAM dose increase. The polymorphic cytochrome P450 2D6 (CYP2D6) strongly determines an individual's capacity for endoxifen formation, however, CYP2D6 phenotype assignments inferred from genotype widely differ between studies. Thus, we modeled plasma endoxifen pre...

Journal: :Clinical chemistry 2005
María C Ledesma José A G Agúndez

BACKGROUND Cytochrome P450 2D6 (CYP2D6) is one of the best-known polymorphic drug-metabolizing enzymes. Rapidly evolving genotyping techniques permit the identification of single-nucleotide polymorphisms (SNPs) and thereby a prediction of individual metabolic capacities for CYP2D6 substrates. A considerable part of interindividual variability in CYP2D6 enzyme activity, however, is not related t...

2016
Getinet Ayano

Psychotropic medications metabolized by cytochromes P450 (CYP) 2D6 are reviewed, and the possible relevance of this metabolism to drug-drug interactions is discussed. CYP2D6 is a member of the cytochrome P450 super family and it plays a primary role in the metabolism of more than 70 substrate medications, belonging to classes such as antidepressants, antipsychotics, mood stabilizers, antiarthem...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2006
Ai-Ming Yu Robert L Haining

Metabolism of the prototype human CYP2D6 substrates debrisoquine and bufuralol proceeds at a much slower rate in mice; therefore, the mouse has been proposed as an animal model for the human CYP2D6 genetic deficiency. To interpret the molecular mechanism of this deficiency, a cDNA belonging to the CYP2D gene subfamily (Cyp2d22) has been cloned and sequenced from a mouse mammary tumor-derived ce...

2001

It has earlier been shown that the isoenzymes CYP2D6 and CYP3A4 are involved in Oand N-demethylation of diltiazem (DTZ), respectively. Apparently, CYP3A4 plays a more prominent role than CYP2D6 in the overall metabolism of DTZ. However, previous observations indicate that the opposite might be true for the pharmacologically active metabolite desacetyl-DTZ (M1). Thus, the aim of the present in v...

2001

It has earlier been shown that the isoenzymes CYP2D6 and CYP3A4 are involved in Oand N-demethylation of diltiazem (DTZ), respectively. Apparently, CYP3A4 plays a more prominent role than CYP2D6 in the overall metabolism of DTZ. However, previous observations indicate that the opposite might be true for the pharmacologically active metabolite desacetyl-DTZ (M1). Thus, the aim of the present in v...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2002
Espen Molden Anders Asberg Hege Christensen

It has earlier been shown that the isoenzymes CYP2D6 and CYP3A4 are involved in O- and N-demethylation of diltiazem (DTZ), respectively. Apparently, CYP3A4 plays a more prominent role than CYP2D6 in the overall metabolism of DTZ. However, previous observations indicate that the opposite might be true for the pharmacologically active metabolite desacetyl-DTZ (M1). Thus, the aim of the present in...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید